Online Formulary

11.6. Retinal Disorders

Click Here for Kent and Medway Health Economy National Tariff Excluded Drugs Manual -High Cost Drugs

Aflibercept (Eylea®)	This High-Cost Drug has been approved for the following indications:- Treatment of neovascular age-related macular degeneration (nAMD) and Macular oedema due to diabetes (DMO)
For more information Click Here	Aflibercept 114.3 mg/mL (8mg/0.07ml) solution for injection (in a vial presentation) via intravitreal administration ICB commissioned - approval via Blueteq

Brolucizumab (Beovu®)	This High-Cost Drug has been approved for the following indications:- Visual impairment due to diabetic macular oedema in adults. Brolucizumab will be reserved as a last line treatment option following failure to either aflibercept, faricimab and ranibizumab.
For more information and NICE Guidance Click Here	Brolucizumab for treating diabetic macular oedema NICE Guidance TA820 ICB commissioned - approval via Blueteq

Dexamethasone intravitreal implant (Ozurdex^®)	This High-Cost Drug has been approved for the following indications:- Treatment of diabetic macular oedema (DMO)
For more information and NICE Guidance Click Here	Dexamethasone intravitreal implant for treating diabetic macular oedema NICE Guidance TA824 ICB commissioned - approval via Blueteq

Faricimab (Vabysmo®)	This High-Cost Drug has been approved for the following indications:- Diabetic Macular Oedema (DMO), and Neovascular (wet) age-related macular degeneration (wetAMD)
	Faricimab for treating diabetic macular oedema NICE Guidance TA799
For more information and NICE Guidance Click Here	Faricimab for treating wet age-related macular degeneration NICE Guidance TA800 ICB commissioned - approval via Blueteq

Fluocinolone acetonide (Iluvien®)	This High-Cost Drug has been approved for the following indications:- for treating chronic diabetic macular oedema that has not responded well enough to available treatments in adults. NICE Guidance
For more information and NICE Guidance Click Here	Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema NICE Guidance TA953 ICB commissioned - approval via Blueteq

Ranibizumab Biosimilar (Lucentis®/ Ongavia®)	This High-Cost Drug has been approved for the following indications:- Neovascular (wet) age-related macular degeneration, Diabetic macular oedema, Macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), and Choroidal neovascularisation.
	Ranibizumab and pegaptanib for the treatment of age-related macular degeneration NICE Guidance TA155 ICB commissioned - approval via Blueteq
For more information and NICE Guidance Click Here	Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion NICE Guidance TA283 ICB commissioned - approval via Blueteq
	Ranibizumab for treating diabetic macular oedema NICE Guidance TA274 ICB commissioned - approval via Blueteq
	Ranibizumab for treating choroidal neovascularisation associated with pathological myopia NICE Guidance TA298 ICB commissioned - approval via Blueteq

First Line Choice
On Formulary
Specialist Initiation Only

Hospital Only
KMPT Initiation Only